We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+22.06%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$464M
AUM Growth
+$5.56M
Cap. Flow
-$35.8M
Cap. Flow %
-7.71%
Top 10 Hldgs %
82.23%
Holding
26
New
2
Increased
2
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.85M
2
AKAO
Achaogen Inc
AKAO
+$297K

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$13.6M
2
BPMC
Blueprint Medicines
BPMC
+$11.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$7.26M
4
IMMU
Immunomedics Inc
IMMU
+$3.18M
5
AIMT
Aimmune Therapeutics
AIMT
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 50.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKAO
26
PUT
DELISTED
Achaogen Inc
AKAO
– –
-200,000
Closed -$2.6M
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q2 2018 Portfolio in Review

As of Q2 2018, Foresite Capital Management III held 26 positions worth $464M, up 1.2% from $459M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Foresite Capital Management III withdrew a net $35.8M in Q2 2018, closing 2 positions and reducing 9 holdings. Its most notable exit was Ra Pharmaceuticals, Inc. Common Stock, an estimated $266K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 53% a quarter earlier.

Against the trend, Foresite Capital Management III added an estimated $1.85M to SANGAMO THERAPEUTICS INC.

  • Foresite Capital Management III added most to SANGAMO THERAPEUTICS INC in Q2 2018, an estimated $1.85M increase.
  • Foresite Capital Management III's biggest Q2 2018 reduction was Aerie Pharmaceuticals, cutting an estimated $13.6M.
  • Foresite Capital Management III fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2018, selling an estimated $266K.
  • Foresite Capital Management III's ten largest holdings make up 82% of its $464M portfolio in Q2 2018.
  • Foresite Capital Management III opened 2 new positions and closed 2 in Q2 2018.
  • Foresite Capital Management III's portfolio value rose 1.2% quarter-over-quarter to $464M.

Based on Foresite Capital Management III's 13F filing for Q2 2018, filed 14 Aug 2018.